News

Gladstone in the News October 16, 2022

How Long Does Immunity from the New COVID Bivalent Boosters Last ’in the Real World’?

San Francisco Chronicle—The new bivalent COVID-19 booster shots are recommended for individuals age 5 and up who are at least two months past their last vaccine dose. Gladstone Investigator Nadia Roan explains that the bivalent boosters greatly increase the levels of antibodies that can prevent the Omicron variant from infecting cells.

Gladstone Experts COVID-19 Infectious Disease Roan Lab

Article September 28, 2022

Gladstone Institutes Joins the Parker Institute for Cancer Immunotherapy Network

The new research center will accelerate cures for the world’s gravest cancers

Institutional News News Release Cancer Marson Lab

Photo Album September 21, 2022

Celebrating the 2022 PUMAS Interns

View highlights from Gladstone’s 2022 summer internship program

People Services Postdoctoral and Graduate Student Education and Research Development Affairs Student Outreach and Science Education Graduate Students and Postdocs

Article September 21, 2022

Meet Gladstone: Alessandra Rios Canelo

Benefits Coordinator Alessandra Rios Canelo shares her favorite part of working at Gladstone, how she spends her free time, and the importance of Latinx Heritage Month.

People Services Profile Diversity

Article September 20, 2022

Gladstone Hosts the First Vilcek Science Symposium to Celebrate Immigrant Scientists

The symposium will provide a platform for sharing research, launching collaborations, and mentoring young immigrant scientists

Institutional News

Article September 16, 2022

Here’s What 6 Scientists Have to Say about Alzheimer’s Disease Research

For World Alzheimer’s Month, researchers talk about their work and hopes of finding new treatments for this debilitating disease

Alzheimer’s Disease Neurological Disease

Gladstone in the News September 10, 2022

When’s the Best Time to Get the New COVID Booster Shot? Here’s What Experts Say

San Francisco Chronicle—New COVID-19 booster shots targeting both the ancestral virus and omicron strains are now available. Gladstone Investigator Nadia Roan weighs in on when people should get the jab, based on the timing of their last dose and whether they’ve been recently infected.

Gladstone Experts COVID-19 Infectious Disease Roan Lab

Article September 9, 2022

New Antiviral Therapy May Block COVID-19 Transmission

The single-dose, intranasal treatment also reduces symptoms of multiple variants of the SARS-CoV-2 virus

News Release Research (Publication) COVID-19 Center for Cell Circuitry Infectious Disease Weinberger Lab Chaturvedi

Article September 6, 2022

Where Computation and Experimentation Collide

Christina Theodoris joins Gladstone as an assistant investigator to find new therapies for people with life-threatening cardiovascular diseases

Institutional News News Release Profile Cardiovascular Disease Data Science and Biotechnology Theodoris Lab

Gladstone in the News September 1, 2022

CDC Authorizes New Omicron-Specific Booster Shots against COVID

San Francisco Chronicle—Senior Investigator Warner Greene, MD, PhD, says that it makes more sense to boost immunity with the newly approved bivalent vaccines targeting Omicron than with vaccines that aim at long-extinct variants of the coronavirus.

Gladstone Experts COVID-19 Center for HIV Cure Research Infectious Disease Greene Lab

Article September 1, 2022

Revealing Molecular Switches for Heart Disease

Michael Alexanian joins Gladstone Institutes to discover new targets for treating and reversing heart failure

Institutional News News Release Profile Heart Failure Cardiovascular Disease Alexanian Lab

Article August 30, 2022

Here’s What You Should Know about Monkeypox

Gladstone scientists address the basics—and dispel misconceptions—about MPXV

Gladstone Experts MPXV Infectious Disease

Gladstone in the News August 29, 2022

A Better, Faster, More Effective Way to Edit Genes

Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology, comments on breakthrough technology developed in his lab that will greatly facilitate the large-scale engineering of immune cells for cell-based therapies.

Gladstone Experts Genomic Immunology Marson Lab CRISPR/Gene Editing

Article August 25, 2022

A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors

Scientists develop a new approach that produces enough cells for therapeutic applications

News Release Research (Publication) Genomic Immunology Esensten Lab Eyquem Lab Marson Lab CRISPR/Gene Editing

Article August 24, 2022

Giving Immunotherapy Cells Resilience to Pass the “Stress Test”

A Gene Not Previously Known to Regulate Immunity Could Turn Tired T-Cells Around

News Release Research (Publication) Cancer Genomic Immunology Carnevale Lab Marson Lab